SSRIs, SNRIs & Depression Treatment
Canadian Psychiatric Standards Overview

1. Epidemiology of Major Depressive Disorder in North America

Major depressive disorder (MDD) is the leading cause of disability worldwide, according to the World Health Organization's Global Burden of Disease Study. In North America, its prevalence and impact are substantial and growing. The National Survey on Drug Use and Health (NSDUH) estimates that approximately 21 million Americans — roughly 8.4% of the adult population — experienced at least one major depressive episode in 2023.

In Canada, the Mental Health Commission of Canada reports that approximately one in five Canadians will experience a mental health condition in any given year. MDD is the single most prevalent diagnosis, affecting an estimated 3.2 million Canadians (approximately 8.5% of the adult population) annually. The lifetime prevalence of MDD in Canada is approximately 12–13%, consistent with US estimates from the National Comorbidity Survey Replication (NCS-R).

Despite high prevalence, treatment rates remain suboptimal. Canadian epidemiological data indicate that fewer than 50% of individuals with a diagnosable depressive disorder receive evidence-based treatment. Barriers to care include stigma, limited access to psychiatric specialists (particularly in rural and northern Canada), wait times for psychological services, and inadequate recognition of depression in primary care settings. These access challenges have driven significant policy investment in Canadian Collaborative Mental Health Care networks.

2. Neurobiology of Depression: Monoamine Hypothesis and Beyond

The neurobiological underpinnings of major depression are considerably more complex than early monoamine deficiency theories suggested. The foundational monoamine hypothesis — proposed in the 1960s — postulated that depression results from deficient synaptic concentrations of serotonin (5-HT), norepinephrine (NE), and/or dopamine (DA). This hypothesis, while oversimplified, provided the pharmacological rationale for first-generation antidepressants and remains clinically useful as an explanatory framework.

Contemporary neuroscience has expanded this model to incorporate:

• Neuroplasticity hypothesis: Chronic stress reduces Brain-Derived Neurotrophic Factor (BDNF) signaling and hippocampal neurogenesis; antidepressants may restore BDNF levels and synaptic plasticity over weeks — explaining the characteristic delay in clinical antidepressant response
• HPA axis dysregulation: Hyperactivation of the hypothalamic-pituitary-adrenal axis (elevated cortisol) in melancholic depression contributes to hippocampal volume loss and cognitive impairment
• Neuroinflammatory hypothesis: Elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in a subset of depressed patients may impair tryptophan metabolism (kynurenine pathway), reducing serotonin substrate availability
• Glutamatergic dysregulation: The efficacy of NMDA receptor antagonists (ketamine, esketamine) in treatment-resistant depression has highlighted glutamate signaling as a critical target for rapid antidepressant action

These expanded frameworks inform both current pharmacotherapy (standard antidepressants, NMDA antagonists, anti-inflammatory strategies) and emerging treatments under investigation in Canadian academic psychiatric centers.

3. Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs represent the most commonly prescribed antidepressant class in both Canada and the United States, owing to their favorable efficacy-tolerability profile relative to older tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). They are recommended as first-line pharmacotherapy for MDD in the Canadian Psychiatric Association (CPA) guidelines.

Mechanism of action: SSRIs selectively block the serotonin transporter (SERT), preventing reuptake of serotonin from the synaptic cleft into the presynaptic neuron. This increases the concentration and duration of serotonergic signaling at postsynaptic receptors. The selectivity for SERT over norepinephrine transporter (NET) and dopamine transporter (DAT) distinguishes SSRIs from older, less selective agents and accounts for their more favorable adverse effect profile.

DINs shown are representative reference examples. Verify current status via Health Canada Drug Product Database.

Common SSRI Adverse Effects

The adverse effect profile of SSRIs is class-specific rather than agent-specific for most effects. Clinically important adverse effects include:

• GI disturbances (nausea, diarrhea) — most common early in treatment; typically resolve within 2 weeks
• Sexual dysfunction (delayed ejaculation, anorgasmia, decreased libido) — affects 30–40% of patients; may persist with chronic use
• Insomnia or somnolence — agent-dependent (fluoxetine more activating; paroxetine more sedating)
• Weight gain — modest with most SSRIs; paroxetine associated with greater weight gain
• SSRI discontinuation syndrome — abrupt cessation produces flu-like symptoms, sensory disturbances ("brain zaps"), irritability; fluoxetine least affected due to long half-life
• Serotonin syndrome risk — with concurrent serotonergic agents (triptans, tramadol, MAOIs, linezolid, St. John's Wort)

4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs inhibit both SERT and NET, increasing synaptic concentrations of both serotonin and norepinephrine. This dual mechanism provides additional therapeutic benefit in conditions with prominent noradrenergic components — particularly neuropathic pain, anxiety disorders, and attention-related symptoms of depression. SNRIs are recommended alongside SSRIs as first-line antidepressant options in the CPA CANMAT guidelines.

Key clinical distinction from SSRIs: The noradrenergic component of SNRIs may be associated with blood pressure elevation, tachycardia, and urinary hesitancy (particularly in men with prostatic hypertrophy) — adverse effects not typically seen with pure SSRIs. SNRIs may also provide superior analgesia in comorbid neuropathic pain conditions, an important consideration in Canadian primary care.

5. Atypical Antidepressants

Several antidepressants with unique or multimodal mechanisms do not fit cleanly within the SSRI/SNRI classification. These agents offer clinically valuable alternative profiles for patients intolerant to or inadequately responsive to first-line agents.

6. Tricyclic Antidepressants (TCAs) & MAOIs: Historical Context and Current Use

TCAs (amitriptyline, nortriptyline, imipramine, clomipramine) and MAOIs (phenelzine, tranylcypromine) preceded SSRIs and SNRIs by decades and remain in clinical use, though as second- or third-line options due to their less favorable safety and tolerability profiles.

TCAs inhibit both SERT and NET but also antagonize muscarinic acetylcholine receptors, histamine H1 receptors, and alpha-1 adrenergic receptors — producing their characteristic side effect triad of anticholinergic effects (dry mouth, constipation, urinary retention, cognitive impairment), sedation, and orthostatic hypotension. Cardiotoxicity (QRS prolongation, ventricular arrhythmias) makes TCAs particularly dangerous in overdose — a significant clinical consideration in MDD given the associated suicide risk.

MAOIs irreversibly inhibit monoamine oxidase A and B, preventing degradation of serotonin, norepinephrine, and dopamine. While highly efficacious (particularly for atypical depression), their requirement for a tyramine-restricted diet (to prevent hypertensive crises) and extensive drug-drug interaction profile limit their contemporary use. Reversible inhibitors of monoamine oxidase A (RIMAs) such as moclobemide — more commonly prescribed in Canada than the US — offer a somewhat improved safety profile.

7. Comparative Clinical Profiles: Key Decision Factors

8. Canadian Psychiatric Association (CPA) Treatment Guidelines

The CANMAT (Canadian Network for Mood and Anxiety Treatments) Clinical Guidelines, endorsed by the Canadian Psychiatric Association, represent the most widely referenced evidence-based framework for antidepressant prescribing in Canada. The 2023 CANMAT revision reflects emerging evidence on biological, psychological, and social treatment approaches.

CANMAT guidelines emphasize that psychotherapy — particularly cognitive behavioral therapy (CBT), interpersonal therapy (IPT), and behavioral activation — is equally efficacious to pharmacotherapy in mild-to-moderate MDD and should be offered alongside or instead of medication when accessible. Combination pharmacotherapy and psychotherapy demonstrates superior outcomes over either modality alone for moderate-to-severe MDD.

9. Health Canada Antidepressant Regulatory Standards

All antidepressant medications marketed in Canada require Health Canada approval under the New Drug Submission (NDS) framework, demonstrating safety and efficacy through randomized controlled trial evidence. Health Canada has issued several significant regulatory actions regarding antidepressants, including:

• Black box warnings (equivalent to FDA black box): Health Canada requires prominent warnings regarding increased suicidality risk in pediatric, adolescent, and young adult patients (up to age 24) during initial antidepressant therapy — consistent with FDA labeling requirements
• Citalopram QTc warning (2012): Health Canada issued a safety advisory limiting citalopram maximum dose to 40 mg/day in adults (20 mg/day in elderly) due to dose-dependent QTc prolongation risk
• Generic bioequivalence standards: All generic antidepressants approved via ANDS must meet the 80–125% bioequivalence CI standard, with DIN assignment and listing in the Health Canada Drug Product Database

In Canada, all antidepressants (including OTC-equivalent formulations marketed in some other countries) require a Schedule F prescription. Dispensing by CIPA-certified pharmacies requires a valid Canadian or US physician prescription. Post-market safety monitoring occurs through the Canada Vigilance Program, and patients are encouraged to report adverse events directly to Health Canada.